BR0115859A - Método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina - Google Patents

Método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina

Info

Publication number
BR0115859A
BR0115859A BR0115859-7A BRPI0115859A BR0115859A BR 0115859 A BR0115859 A BR 0115859A BR PI0115859 A BRPI0115859 A BR PI0115859A BR 0115859 A BR0115859 A BR 0115859A
Authority
BR
Brazil
Prior art keywords
structures
aggregated
vaccine
antigenic
formulations
Prior art date
Application number
BR0115859-7A
Other languages
English (en)
Inventor
Julio Cesar Aguilar Rubido
Eduardo Penton Arias
Dina Tleugabulova
Minerva Sewer Mensies
Verena Lucila Muzio Gonzalez
Gerard Enrique Guillen Nieto
Iioki Assanga Simon Bernard
Luis Javier Cruz Ricondo
Viviana Falcon Cama
Yanet Tambara Hernandez
Original Assignee
Ct De Ingebieria Genetica Y Bi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingebieria Genetica Y Bi filed Critical Ct De Ingebieria Genetica Y Bi
Publication of BR0115859A publication Critical patent/BR0115859A/pt
Publication of BRPI0115859B1 publication Critical patent/BRPI0115859B1/pt
Publication of BRPI0115859B8 publication Critical patent/BRPI0115859B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO DE OBTENçãO DE ESTRUTURAS ANTIGêNICAS AGREGADAS DE ALTA IMUNOGENICIDADE, ESTRUTURA ANTIGêNICA AGREGADA, FORMULAçãO DE VACINA E USOS DE UMA ESTRUTURA ANTIGêNICA E DE FORMULAçõES DE VACINA". Esta invenção refere-se a um método de obtenção de estruturas antigênicas agregadas, capazes de potenciar a resposta imunológica a antígenos agregados administrados por via sistêmica e/ou mucosal, bem como às estruturas químicas, formulações de referidas estruturas e a seu uso. A partir do uso de agentes ou compostos agregadores, delipidantes ou oxidantes, permite-se a liberação de lipídeos das partículas e a agregação das mesmas. O estado de agregação pode ser provocado no interior da levedura variando-se as condições de incubação. As estruturas resultantes podem ser utilizadas adjuvadas e/ou com vários antígenos, produzindo-se sinergismo entre os componentes com relação à resposta imunogênica, podendo conter estabilizadores e conservantes. Estas novas estruturas antigênicas são aplicáveis na indústria como formulações de vacina, preventivas ou terapêuticas, para uso humano, veterinário e/ou diagnóstico.
BRPI0115859-7 2000-12-01 2001-11-29 método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina BRPI0115859B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2000-0279 2000-12-01
CU20000279A CU23002A1 (es) 2000-12-01 2000-12-01 Método de obtención de agregados antigénicos y su uso en formulaciones
PCT/CU2001/000009 WO2002043756A2 (es) 2000-12-01 2001-11-29 Método de obtención de agregados antigénicos y su uso en formulaciones

Publications (3)

Publication Number Publication Date
BR0115859A true BR0115859A (pt) 2003-12-30
BRPI0115859B1 BRPI0115859B1 (pt) 2020-10-13
BRPI0115859B8 BRPI0115859B8 (pt) 2021-05-25

Family

ID=5459569

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0115859-7 BRPI0115859B8 (pt) 2000-12-01 2001-11-29 método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina

Country Status (17)

Country Link
US (2) US20040202676A1 (pt)
EP (1) EP1346727B1 (pt)
JP (1) JP4974441B2 (pt)
KR (1) KR100873675B1 (pt)
CN (1) CN1253206C (pt)
AR (1) AR031437A1 (pt)
AT (1) ATE465752T1 (pt)
AU (2) AU2002221518B2 (pt)
BR (1) BRPI0115859B8 (pt)
CA (1) CA2429543C (pt)
CU (1) CU23002A1 (pt)
DE (1) DE60141978D1 (pt)
ES (1) ES2342150T3 (pt)
PT (1) PT1346727E (pt)
RU (1) RU2266754C2 (pt)
WO (1) WO2002043756A2 (pt)
ZA (1) ZA200303948B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
EP1652914A1 (en) * 2004-10-27 2006-05-03 Berna Biotech AG Virosome particles comprising antigens from influenza virus and Hepatitis B virus
US9603921B2 (en) 2004-10-27 2017-03-28 Janssen Vaccines Ag Virosome particles comprising antigens from influenza virus and hepatitis b virus
DK1917029T3 (da) 2005-07-27 2013-04-29 Lilly Co Eli Fremgangsmåde til at behandle cancerceller og skabe en modificeret cancercelle, som provokerer et immunogent respons
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
AR107262A1 (es) 2016-01-27 2018-04-11 Lilly Co Eli Inactivación de patógenos por delipidación
EA201892212A1 (ru) * 2016-03-31 2019-03-29 Сентро Де Инхеньерия Хенетика И Биотекнолохия Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
EP1294893B1 (en) * 2000-06-22 2006-03-15 UCB Pharma Limited Modification of hepatitis b core antigen
US8092734B2 (en) * 2004-05-13 2012-01-10 Aptina Imaging Corporation Covers for microelectronic imagers and methods for wafer-level packaging of microelectronics imagers

Also Published As

Publication number Publication date
AU2151802A (en) 2002-06-11
US20040202676A1 (en) 2004-10-14
CN1253206C (zh) 2006-04-26
DE60141978D1 (de) 2010-06-10
WO2002043756A3 (es) 2003-01-09
JP4974441B2 (ja) 2012-07-11
BRPI0115859B8 (pt) 2021-05-25
CA2429543C (en) 2012-07-10
AU2002221518B2 (en) 2006-06-01
KR100873675B1 (ko) 2008-12-11
CA2429543A1 (en) 2003-05-20
PT1346727E (pt) 2010-05-21
EP1346727B1 (en) 2010-04-28
CN1477972A (zh) 2004-02-25
JP2004529861A (ja) 2004-09-30
AR031437A1 (es) 2003-09-24
ATE465752T1 (de) 2010-05-15
BRPI0115859B1 (pt) 2020-10-13
WO2002043756A2 (es) 2002-06-06
US20090104223A1 (en) 2009-04-23
EP1346727A2 (en) 2003-09-24
RU2266754C2 (ru) 2005-12-27
ZA200303948B (en) 2004-03-30
KR20030068161A (ko) 2003-08-19
ES2342150T3 (es) 2010-07-02
CU23002A1 (es) 2004-11-18

Similar Documents

Publication Publication Date Title
RU2349342C2 (ru) Менингококковые вакцины для введения через слизистую оболочку
KR101056622B1 (ko) 미코플라스마 하이오뉴모니애 및 돼지 바이러스에 대한개선된 배합 백신
ES2398235T3 (es) Emulsiones de aceite en agua microfluidizadas y composiciones de vacunas
HU202119B (en) Adjuvant mixture and process for producing vaccine comprising same
ES2233955T3 (es) Adyuvantes para vacunas viricas.
ES2180703T5 (es) Composiciones de vacunas para mamiferos que comprenden escualeno o escualano, un fosfolipido y un tensioactivo como adyuvante.
CN102112135A (zh) 包含合成佐剂的疫苗组合物
KR20130112790A (ko) 백신 조성물
ES2924988T3 (es) Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
US9585955B2 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
CN111671894B (zh) 一种基于铝佐剂的疫苗递送系统及其制备方法
NZ531526A (en) Interleukin-12 as a veterinary vaccine adjuvant
US9750692B2 (en) Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
US6890540B1 (en) Vaccine formulation
BRPI0115859B8 (pt) método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina
EP1154792B1 (en) Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
Nielsen et al. ISCOMs as a vaccine delivery system
CN104427998A (zh) 佐剂
CN1161154C (zh) 用于疫苗的免疫增强制剂
BR0107424A (pt) Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma
CN1301572A (zh) 用于疫苗的佐剂组合物
CN104208664B (zh) 一种鼻用疫苗组合物液体制剂及其制备方法
Donnelly New developments in adjuvants
Acosta et al. TB VACCINES BASED ON PROTEOLIPOSOMES AND LIPOSOMES FROM NON PATHOGENIC MYCOBACTERIA
WO2003059383A1 (es) COMPOSICÍON DE VACUNA FRENTE A LA BRUCELOSIS QUE COMPRENDE MICROPARTÍCULAS DE POLI(ϵ-CAPROLACTONA) COMO ADYUVANTE

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/11/2021